[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628256":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":21,"responsibleParty":34,"collaborators":10,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":65,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Methamphetamine-Induced Psychotic Disorder + Lifetime Cannabis Use (MP + LCU)",null,"Adult male participants (18-65 years) diagnosed with Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria. No intervention was\u002Fwill be assigned by the study protocol. At baseline, participants will complete a sociodemographic and clinical information form. Psychiatric symptoms and addiction-related characteristics will be assessed using standardized psychometric scales. Participants will then be followed prospectively for eight weeks. The scales will be used in this study are as follows: Insight Assessment Scale, Addiction Profile Index Clinical-Practitioner Form, Positive and Negative Syndrome Scale, Global Assessment Scale, Pittsburgh Sleep Quality Index.",{"label":13,"type":10,"description":14,"interventionNames":10},"Methamphetamine-Induced Psychotic Disorder - Lifetime Cannabis Use (MP - LCU)","Adult male participants (18-65 years) diagnosed with Methamphetamine-Induced Psychotic Disorder (no lifetime cannabis use) according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria. No intervention was\u002Fwill be assigned by the study protocol. At baseline, participants will complete a sociodemographic and clinical information form. Psychiatric symptoms and addiction-related characteristics will be assessed using standardized psychometric scales. Participants will then be followed prospectively for eight weeks. The scales will be used in this study are as follows: Insight Assessment Scale, Addiction Profile Index Clinical-Practitioner Form, Positive and Negative Syndrome Scale, Global Assessment Scale, Pittsburgh Sleep Quality Index.",[16],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist","CONTACT","+905382207558","mhorum@hotmail.com",[22],{"facility":5,"status":10,"city":23,"state":23,"zip":24,"country":25,"countryCode":10,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Elâzığ","23200","Turkey (Türkiye)",{"type":27,"coordinates":28},"Point",[29,30],39.22321,38.67431,{"lat":30,"lon":29},[33],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mehmet Hamdi ÖRÜM","Associate Professor, MD, Psychiatrist","100628256","psychiatric-symptom-characteristics-in-methamphetamine-induced-psychosis-with-and-without-lifetime-cannabis-use-100628256",false,"NCT07459270","Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use","Investigation of Factors Associated With Psychiatric Symptoms in Participants Diagnosed With Methamphetamine-Induced Psychotic Disorder With and Without Lifetime Cannabis Use","1. For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n   * Diagnosis of Cannabis Use Disorder according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder plus Lifetime Cannabis Use (MP + LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n\n   • Rheumatoid arthritis\n\n   • Systemic lupus erythematosus\n\n   • Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Inclusion Criteria:\n\n   • Diagnosis of MP according to DSM-5-TR\n\n   • Medication-free for at least one month prior to admission\n\n   • Age ≥ 18 years and \\\u003C65 years\n\n   • Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP without LCU) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n\n   • Diabetes mellitus\n\n   • Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder",true,"MALE","18 Years","65 Years",{"count":50,"type":51},90,"ESTIMATED","OBSERVATIONAL","This prospective cohort study aims to investigate factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP) with and without lifetime cannabis use (LCU). Participants hospitalized at Elazığ Mental Health and Diseases Hospital who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for MP will be included.\n\nParticipants will be divided into two groups based on the presence or absence of LCU. Psychiatric symptoms and clinical characteristics will be assessed weekly during an eight-week inpatient follow-up period using standardized psychometric instruments.\n\nThe study aims to determine whether LCU influences the course and severity of psychiatric symptoms in MP and to identify environmental, individual, and familial factors associated with symptom progression.",[55,56],"Methamphetamine Induced Psychosis","Cannabis Use",[58,59,60,61,62,63,64],"Methamphetamine","Cannabis","Marijuana","Psychiatric Symptoms","Longitudinal Study","Methamphetamine-Induced Psychotic Disorder","Lifetime Cannabis Use","NOT_YET_RECRUITING","2026-03-04",{"date":68,"type":69},"2026-03-09","ACTUAL",{"date":71,"type":51},"2026-03-16",{"date":73,"type":51},"2026-11-23",{"name":5,"class":6},1]